PaxMedica announces publication of ASD Phase 2 study results

PaxMedica announced the publication of research findings in the Annals of General Psychiatry. The research, led by Chief Medical Officer Dr. David Hough, along with a team of renowned co-authors specializing in Autism Spectrum Disorder, the research explores the potential of low-dose suramin intravenous infusions as an ASD treatment. This comprehensive, 14-week randomized, double-blind, placebo-controlled study enrolled 52 boys aged 4-15 years with moderate to severe ASD. The primary focus of the study was to evaluate the efficacy and safety of suramin intravenous infusions, with the 10 mg/kg suramin arm demonstrating promising results in the improvement of core symptoms. Notably, the study revealed statistically significant improvements in the Clinical Global Impressions-Improvement scale among the 10 mg/kg arm compared to the placebo group. The study, registered with clinicaltrials.gov, serves as a significant advancement in understanding potential treatment options for ASD. With a continued commitment to pioneering research in neurological disorders, PaxMedica remains dedicated to enhancing the quality of life for individuals living with ASD.